SUVENPHAR2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2020-07-012020-09-30in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2020-07-012020-09-30in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2020-07-012020-09-30in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2020-07-012020-09-30in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2020-04-01 2021-03-31 2020-10-23 INR Lakhs Half yearly true Cash Flow Indirect Single segment Contract Development and ManufacturingnOperations (CDMO) 2020-07-01 2020-09-30 Unaudited Standalone 2373881000.00 3568000.00 2377449000.00 771795000.00 0.00 -35565000.00 209290000.00 32629000.00 75002000.00 443428000.00 1496579000.00 880870000.00 0.00 880870000.00 216392000.00 11178000.00 227570000.00 0.00 653300000.00 0.00 0.00 0.00 0.00 653300000.00 -2044000.00 651256000.00 0.00 0.00 254565000.00 1 2.57 2.57 0.00 0.00 2.57 2.57 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30th October, 2020. The above results have been subjected to limited review by the statutory auditors of the company. n2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. n3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma Inc., and Associate Rising Pharma Holdings Inc. n4) The Board has allotted the Bonus shares at 1:1 ratio in it's Board Meeting held on 29th Sept, 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated. The paid-up capital on account of Bonus issue of Rs.1272.82 lakhs has been appropriated from Share premium account. n5) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. n6) Consequent to the demerger of Contract Research and Manufacturing services (CRAMS) Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October, 2018. The Suven Life Sciences Limited (SLSL/Demerged Company) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable the Company (SPL) to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the SLSL is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL. n7) The Board has approved CAPEX plan of INR 60,000 lakhs keeping in view of the proposed increase in capacity in Pashamylaram facility, replacement and modernization of old production blocks in Suryapet facility, relocation of R&D facilities from Jeedimetla and acquisition of new technologies. n8) On 30 January’ 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a “Public Health Emergency of International Concern” and on 11 March’ 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. During this period, the Company has experienced minor disruptions impacting our operations even though there were no major consequences which will materially affect the Company. n9) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended Sept 30, 2020, the company has written-off net book value of assets aggregating Rs 109.30 Lakhs and recognised a minimum insurance claim receivable for equivalent amount. n10) The corresponding previous period figures have been regrouped / reclassified where ever necessary. Single segment 2020-04-01 2020-09-30 Unaudited Standalone 4756205000.00 60959000.00 4817164000.00 1431822000.00 0.00 11899000.00 383732000.00 64691000.00 145636000.00 822745000.00 2860525000.00 1956639000.00 0.00 1956639000.00 489264000.00 1775000.00 491039000.00 0.00 1465600000.00 0.00 0.00 0.00 0.00 1465600000.00 -4089000.00 1461511000.00 0.00 0.00 254565000.00 1 5.76 5.76 0.00 0.00 5.76 5.76 Manufacturing Expenses 297064000.00 Other Expenses 108222000.00 R & D Expenses 38142000.00 Manufacturing Expenses 535935000.00 Other Expenses 217883000.00 R & D Expenses 68927000.00 64691000.00 -226160000.00 116524000.00 0.00 -322857000.00 81947000.00 0.00 0.00 0.00 92362000.00 0.00 -13078000.00 0.00 143972000.00 0.00 22334000.00 0.00 -61560000.00 0.00 0.00 0.00 1806000.00 0.00 -15539000.00 0.00 0.00 0.00 0.00 0.00 -119170000.00 1837469000.00 0.00 0.00 0.00 405996000.00 0.00 1431473000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 628476000.00 -388802000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19984000.00 0.00 -1037262000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27593000.00 362343000.00 0.00 -9464000.00 0.00 64691000.00 0.00 1014000.00 -388963000.00 5248000.00 0.00 5248000.00 115768000.00 121016000.00